Sign Out
Metformin plus liraglutide eases glycemia but not gluconeogenesis in youth-onset T2D
Use of metformin with or without liraglutide results in improved glycaemia but falls short of suppressing the high rates of gluconeogenesis in patients with youth-onset type 2 diabetes (Y-T2D), reports a study.
Use of metformin with or without liraglutide results in improved glycaemia but falls short of suppressing the high rates of gluconeogenesis in patients with youth-onset type 2 diabetes (Y-T2D), reports a study.
Improving outcomes with a soluble guanylate cyclase stimulator in patients with worsening HF
Although guideline-directed medical therapies (GDMTs) for heart failure (HF) with reduced ejection fraction (HFrEF) are effective in reducing risks of mortality and hospitalization for HF (HHF), the clinical burden of HF remains high. At a recent scientific symposium, Dr Yuya Matsue of Juntendo University Graduate School of Medicine in Japan discussed strategies of tackling worsening HF (WHF) to improve patient outcomes and presented a case study of vericiguat in HFrEF.
Although guideline-directed medical therapies (GDMTs) for heart failure (HF) with reduced ejection fraction (HFrEF) are effective in reducing risks of mortality and hospitalization for HF (HHF), the clinical burden of HF remains high. At a recent scientific symposium, Dr Yuya Matsue of Juntendo University Graduate School of Medicine in Japan discussed strategies of tackling worsening HF (WHF) to improve patient outcomes and presented a case study of vericiguat in HFrEF.
Spikevax XBB.1.5
Contents : Andusomeran [COVID-19 mRNA vaccine (nucleoside modified)]
Indications/Uses : Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals ≥12 yr.
Enhertu
Contents : Trastuzumab deruxtecan
Indications/Uses : Monotherapy for the treatment of adult patients w/ unresectable or metastatic HER2 +ve breast cancer who have received ≥1 prior anti-HER2-based regimens. Monotherapy for the treatment of adult patients w/ unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or w/in 6 mth of completing adjuvant chemotherapy. Monotherapy for the treatment of adult patients w/ advanced HER2 +ve gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
